A Clinical Study of Liposomal Irinotecan for Second-Line Therapy in Metastatic Colorectal Cancer

NCT07585279 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

NOT_YET_RECRUITING

Status

408

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Cancer (CRC)
Liposomal Irinotecan
Second-Line

Interventions

DRUG: Liposomal irinotecan + 5-FU/LV + bevacizumab + Enlonstobart
DRUG: Irinotecan liposome + 5-FU/LV + Bevacizumab
DRUG: Irinotecan + 5-FU/LV + Bevacizumab

Sponsor

Hebei Medical University Fourth Hospital